<DOC>
	<DOCNO>NCT01151761</DOCNO>
	<brief_summary>The purpose study determine progression-free survival 12 month stereotactic body radiotherapy ( SBRT ) chemotherapy unresectable hilar cholangiocarcinoma ( CCA ) .</brief_summary>
	<brief_title>Phase II SBRT &amp; Chemo Unresectable Cholangiocarcinoma Followed Liver Transplantation</brief_title>
	<detailed_description>Investigators hope learn neoadjuvant SBRT chemotherapy unresectable CCA , SBRT follow chemotherapy lead successful liver transplantation . This knowledge important patient group disease highly lethal malignancy often present unresectable , however surgery transplantation curative option .</detailed_description>
	<mesh_term>Liver Neoplasms</mesh_term>
	<mesh_term>Cholangiocarcinoma</mesh_term>
	<mesh_term>Bile Duct Neoplasms</mesh_term>
	<mesh_term>Gallbladder Neoplasms</mesh_term>
	<mesh_term>Liver Extracts</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>Diagnosis cholangiocarcinoma : Positive transcatheter biopsy brush cytology CA 199 &amp; # 8805 ; 100mg/mL malignantappearing stricture cholangiography Biliary ploidy fluorescent situ hybridization malignant stricture cholangiography Liver tumor exceed 8 cm great axial dimension ( 800 cc uninvolved liver ) Unresectable tumor cystic duct Hepatic lesion patient surgical resection possible would result opportunity cure : Bilateral segmental ductal extension Encasement main portal vein Unilateral segmental ductal extension contralateral vascular encasement Unilateral atrophy either contralateral segmental ductal vascular ( hepatic artery , portal vein ) involvement Ascites allow Model EndStage Liver Disease ( MELD ) score &lt; 15 [ 1 ] Age &gt; 18 year old Eastern Clinical Oncology Group performance status 0 , 1 2 ( Appendix 1 ) Lab value within 2 wks prior randomization : See STUDY SCHEMA specific blood count inclusion criterion : ANC &amp; # 8805 ; 500 x 109/L ( &amp; # 8805 ; 1500/mm3 ) , Platelets &amp; # 8805 ; 5 x 109/L ( &amp; # 8805 ; 50,000/mm3 ) , Hgb &amp; # 8805 ; 9g/dL Adequate liver function : Total bilirubin &amp; # 8804 ; 1.5 x upper limit normal ( ULN ) ; ALT and/or AST &amp; alkaline phosphatase &amp; # 8804 ; 5 x ULN . Adequate biliary drainage , evidence active uncontrolled infection ( patient antibiotic eligible ) . See STUDY SCHEMA specific renal function inclusion criterion : Adequate renal function calculate GFR &amp; # 8805 ; 40 ml/min . If calculate GFR 40 ml/min 24 hour urine creatinine clearance use . Albumin &gt; 2.5 mg/dL INR &amp; # 8804 ; 1.5 Life expectancy &gt; 6 month Capable give write informed consent Prior radiotherapy upper abdomen Contraindication receive radiotherapy Prior chemotherapy Prior biliary resection attempt resection Prior transperitoneal biopsy Large esophageal varix without band ligation Active GI bleed within 2 week study enrollment Ascites refractory medical therapy shunt Active/unresolved biliary tract obstruction Presence multifocal , lymphatic , extrahepatic metastasis Participation another concurrent treatment protocol If history primary cancer , subject eligible : Curatively resect nonmelanomatous skin cancer Curatively treat cervical carcinoma situ Other primary solid tumor curatively treat know active disease present treatment administer last 3 year Any evidence severe uncontrolled systemic disease laboratory find view investigator make undesirable patient participate trial Any psychiatric disorder ( eg brain metastasis ) likely impact inform consent Pregnancy breastfeed While exclude , patient significant impaired hearing must make aware potential ototoxicity may choose include . If include , baseline audiogram recommend , give cisplatin , follow repeat audiogram prior cycle 2 .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>